Chronic bacterial vaginosis (BV) is BV that keeps returning despite treatment, typically defined as three or more episodes per year requiring antibiotics. It’s frustratingly common: within 6 to 12 months of finishing antibiotic therapy, 50% to 80% of women will experience a recurrence. Understanding why BV comes back so persistently, and what options exist beyond the standard antibiotic cycle, is key to breaking the pattern.
How Chronic BV Differs From a One-Time Infection
A single episode of BV happens when the balance of bacteria in the vagina shifts. Normally, beneficial bacteria (primarily Lactobacillus species) keep the vaginal environment slightly acidic, which prevents harmful bacteria from taking over. When that balance tips, bacteria like Gardnerella vaginalis multiply, causing the telltale symptoms: a thin gray-white discharge, a fishy odor, and sometimes itching or burning.
Most women clear BV with a course of antibiotics. Chronic BV is different not because the symptoms are worse, but because the underlying disruption never fully resolves. The infection clears temporarily, symptoms disappear, and then weeks or months later, it’s back. For many women, this cycle repeats for years.
Why BV Keeps Coming Back
The main reason chronic BV is so stubborn comes down to biofilms. The bacteria responsible for BV don’t just float freely in the vagina. They form structured communities that attach to the vaginal lining and encase themselves in a protective matrix of carbohydrates, proteins, and genetic material. This biofilm acts as a physical shield against both antibiotics and the body’s own immune defenses.
Research shows that bacteria living inside a biofilm are dramatically more resistant to treatment than the same bacteria floating on their own. In laboratory testing, the standard antibiotics used for BV could stop bacterial growth at normal doses, but the biofilm itself remained intact. Even at the highest concentrations tested, antibiotics could not fully eradicate the biofilm. A small fraction of bacteria always survived. This means standard treatment can eliminate enough bacteria to resolve symptoms, but the biofilm persists, quietly seeding the next recurrence.
The biofilm also makes it possible for the infection to be passed between sexual partners, creating another route for reintroduction even after successful treatment.
Risk Factors That Fuel Recurrence
Several behavioral and lifestyle factors increase the likelihood of BV returning. Douching is one of the most significant because it directly disrupts vaginal acidity, washing away the beneficial bacteria that keep harmful organisms in check. Having new or multiple sexual partners and inconsistent condom use also raise the risk.
Steps that can help lower the chances of recurrence include:
- Avoiding douching entirely. The vagina is self-cleaning, and douching does more harm than good.
- Using condoms consistently. This reduces the exchange of bacteria that can disrupt vaginal flora.
- Limiting the number of sexual partners. Each new partner introduces a different microbial environment.
These steps don’t guarantee prevention, and many women with chronic BV don’t have any obvious risk factors. But removing known triggers gives the vaginal microbiome its best chance of staying balanced.
How Chronic BV Is Diagnosed
Diagnosing BV typically happens one of two ways. The more common method in a clinic setting uses the Amsel criteria, which requires at least three of four findings: a thin, uniform gray-white discharge; vaginal pH above 4.5; a fishy odor when a chemical solution is added to a sample (the “whiff test”); and the presence of clue cells, which are vaginal cells coated in bacteria visible under a microscope.
The other method, called the Nugent score, involves examining a stained vaginal sample to count and compare three types of bacteria. The resulting score ranges from 0 to 10: scores of 0 to 3 are normal, 4 to 6 are intermediate, and 7 or above confirm BV. For chronic BV, the key is documenting that these findings recur across multiple episodes, not just a single visit.
Standard Treatment and Its Limits
First-line treatment for any BV episode is typically a course of antibiotics, either taken orally or applied as a vaginal gel. This works well in the short term. The problem is that for chronic BV, the recurrence rate after a single course is so high that additional strategies are usually needed.
For women with multiple recurrences, a longer suppressive approach is sometimes used. This can involve applying antibiotic gel twice weekly for three months or longer to keep bacteria suppressed. One regimen that has shown some benefit combines an initial week of oral antibiotics, followed by three weeks of vaginal boric acid suppositories, and then several months of twice-weekly antibiotic gel. The challenge is that recurrences often resume once suppressive therapy stops.
Boric Acid as an Add-On Treatment
Boric acid vaginal suppositories have gained attention as a complementary treatment for chronic BV. Used at a dose of 600 mg inserted vaginally at bedtime, typically for 14 consecutive days, boric acid works by lowering vaginal pH and creating an environment that’s hostile to BV-associated bacteria.
In clinical testing, the results were striking. Vaginal odor, present in over 92% of participants at the start, dropped to less than 2% after treatment. Clue cells on microscopy fell from 68% to 8%. Nugent scores shifted from an average of 7.8 (solidly in the BV-positive range) to 3.1 (normal range), with nearly 89% of women achieving a normal score. Side effects were mild, occurring in fewer than 8% of participants, and everyone completed the full course.
Boric acid is not a standalone cure, but as part of a broader treatment plan, it can help reset the vaginal environment and buy time for beneficial bacteria to reestablish.
Rebuilding the Vaginal Microbiome
Because chronic BV is fundamentally a problem of lost microbial balance, restoring beneficial bacteria is a promising strategy. Lactobacillus crispatus is the species most strongly associated with a healthy vaginal environment, and a clinical trial tested a vaginal probiotic containing this strain in 228 women who had just completed antibiotic treatment for BV. After 12 weeks, 30% of the probiotic group had a recurrence compared to 45% in the placebo group. That’s not a perfect solution, but it represents a meaningful reduction.
Other Lactobacillus strains have also shown benefits in clinical studies, including L. rhamnosus, L. plantarum, and L. acidophilus, used either vaginally or orally. One particularly interesting finding is that L. rhamnosus, when introduced early, significantly reduced biofilm thickness and the load of Gardnerella bacteria. This matters because disrupting the biofilm is the piece that standard antibiotics alone struggle to accomplish.
Probiotics are most effective when used after antibiotic treatment rather than instead of it. The antibiotics knock back the harmful bacteria, and the probiotics help fill the ecological gap before BV-associated organisms can regroup.
Health Risks of Untreated Chronic BV
Chronic BV isn’t just an inconvenience. Persistent vaginal inflammation increases vulnerability to sexually transmitted infections, including HIV, chlamydia, and gonorrhea. It also raises the risk of pelvic inflammatory disease, which can cause lasting damage to the reproductive tract.
During pregnancy, the stakes are higher. In one study of pregnant women, 50% of those with BV delivered preterm, compared to 21% of those without it. Delivery before 34 weeks was nearly four times more common in the BV group (22.7% versus 6.2%). Babies born to mothers with BV were more likely to have lower birth weight, need intensive care (41.7% versus 19%), and require breathing support (29.2% versus 7.6%). These numbers underscore why managing chronic BV matters well beyond symptom relief, particularly for women who are pregnant or planning to become pregnant.